Drug intelligence / Profile preview

tiroxime hydrochloride

Development stage: Preclinical
Lead developer: AbbVie
Modality: Small Molecules
Administration: Oral

Overview

Tiroxime hydrochloride is a small molecule compound currently undergoing clinical trials as a potential anti-fibrotic drug. Its primary indication is for the treatment of silicosis, a lung disease caused by long-term inhalation of silica dust. The drug's mechanism of action involves intervening in the process of pulmonary fibrosis by regulating specific signaling pathways, thereby inhibiting the activation and proliferation of fibroblasts. Preclinical studies have shown its ability to significantly reduce the degree of pulmonary fibrosis in experimental animals.

Other names: 盐酸替洛肟

Beyond the preview

Go deeper on tiroxime hydrochloride.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tiroxime hydrochloride.

Explore the full profile